Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their price objective on Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating on the stock in a research report on Thursday, May 2nd.

Minerva Neurosciences Stock Down 2.6 %

Shares of Minerva Neurosciences stock opened at $3.03 on Monday. The stock’s fifty day moving average is $3.10 and its two-hundred day moving average is $4.07. Minerva Neurosciences has a 52 week low of $2.26 and a 52 week high of $13.49. The company has a market capitalization of $21.18 million, a PE ratio of -0.68 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.07. As a group, research analysts anticipate that Minerva Neurosciences will post -1.89 earnings per share for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.